Aurora Cannabis Gets a Buy Rating from GMP FirstEnergy

By Ryan Adsit

Aurora Cannabis (TSXV: ACB), the Materials sector company, was revisited by a Wall Street analyst today. Analyst Martin Landry from GMP FirstEnergy reiterated a Buy rating, with a C$3.25 price target.

According to TipRanks.com, Landry is ranked #573 out of 4572 analysts.

Aurora Cannabis has an analyst consensus of Moderate Buy, with a price target consensus of C$3.20.

The company has a one year high of C$3.95 and a one year low of C$0.40. Currently, Aurora Cannabis has an average volume of 3.42M.

Aurora Cannabis, Inc. operates as a licensed producer of medical marijuana in Canada. Its medical cannabis products include Borealis Blend, Odin, Odin 3, Peechee, Sentinel, Stokes, and Warwick 2. The company was founded by Terry Booth and Steve Dobler on December 21, 2006 and is headquartered in Vancouver, Canada.

The company’s shares closed last Tuesday at $2.50.